As Cilta-Cel’s Big Day Approaches, Legend Looks Beyond Myeloma
Company To Go Solo With T-Cell Lymphoma Program
CEO Ying Huang talked about the biotech’s plans for CAR-T therapies after its J&J-partnered program.
You may also be interested in...
While some cancer centers report sufficient stocks of the drug, they have already been turning to potential alternatives due to supply issues that could last for weeks or months.
Idecabtagene vicleucel for fifth-line multiple myeloma lags GSK’s BCMA-targeting ADC Blenrep, but it is months ahead of J&J/Legend’s CAR-T. Abecma is BMS’s second CAR-T approval this year.
Ying Huang was named CEO as his predecessor came under investigation in China and as partner Janssen was getting closer to seeking US FDA approval for its lead CAR-T therapy.